Revance to Participate in the 43rd Annual Cowen Healthcare Conference

Rhea-AI Summary

Revance Therapeutics, Inc. (RVNC) will participate in the 43rd Annual Cowen Healthcare Conference from March 6-8, 2023, in Boston, Massachusetts. CEO Dustin S. Sjuts and CFO Tobin Schilke will engage in a fireside chat on Monday, March 6 at 9:50 A.M. EST. Interested viewers can access the live audio webcast through the Investor Relations section of their website, with a replay available for 90 days post-event. Revance focuses on developing innovative aesthetic and therapeutic solutions, including DAXXIFY® and a biosimilar to onabotulinumtoxinA, targeting muscle movement disorders.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43^rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts.

President, Dustin S. Sjuts, and Chief Financial Officer, Tobin Schilke, are scheduled to participate in a fireside chat on Monday, March 6, at 9:50 A.M. EST.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005107/en/

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Investor

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Source: Revance Therapeutics, Inc.

FAQ

When will Revance Therapeutics participate in the 43rd Annual Cowen Healthcare Conference?

Revance Therapeutics will participate in the conference from March 6-8, 2023.

Who will represent Revance Therapeutics at the Cowen Healthcare Conference?

CEO Dustin S. Sjuts and CFO Tobin Schilke will represent Revance at the conference.

What time is Revance Therapeutics' fireside chat during the Cowen Healthcare Conference?

Revance's fireside chat is scheduled for March 6 at 9:50 A.M. EST.

How can I access the webcast of Revance Therapeutics' presentation?

The webcast can be accessed via the Investor Relations section of Revance's website.

What products does Revance Therapeutics focus on?

Revance focuses on innovative aesthetic products like DAXXIFY® and therapeutic solutions for muscle movement disorders.

What is RVNC's strategy regarding muscle movement disorders?

RVNC is evaluating DAXXIFY® for conditions such as cervical dystonia and upper limb spasticity.